Back to today’s briefing

Story perspectives

Breakthrough Gene Therapies Offer Hope for Duchenne Muscular Dystrophy

3/20/2025

38 5

Summary

Gene Therapies Advance

Genethon’s GNT0004 gene therapy is making waves in the fight against Duchenne muscular dystrophy (DMD), achieving a remarkable 68% drop in creatine kinase levels and enhancing motor skills in young boys. Simultaneously, REGENXBIO’s RGX-202 is showcasing strong microdystrophin expression with a solid safety profile. Together, these breakthroughs offer hope and new possibilities for families battling DMD.

Summary

Researchers Develop Therapy

A groundbreaking gene therapy for Dravet syndrome, a devastating epilepsy impacting 1 in 15,700 children, has been developed by researchers at the Allen Institute in Seattle. In tests on mice, the treatment demonstrated lasting recovery without adverse effects. With plans for clinical trials underway, this innovation brings renewed hope to families seeking effective solutions.

1 of 2

Gene Therapies Advance

Genethon’s GNT0004 gene therapy is making waves in the fight against Duchenne muscular dystrophy (DMD), achieving a remarkable 68% drop in creatine kinase levels and enhancing motor skills in young boys. Simultaneously, REGENXBIO’s RGX-202 is showcasing strong microdystrophin expression with a solid safety profile. Together, these breakthroughs offer hope and new possibilities for families battling DMD.

1 / 2